Last reviewed · How we verify
Other antidiabetic therapies
At a glance
| Generic name | Other antidiabetic therapies |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- iGlarLixi CGM Study in Chinese T2D Individuals After OADs (PHASE4)
- Transformative Research in Diabetic Nephropathy 2.0
- A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes (PHASE3)
- Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
- Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease (PHASE4)
- Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes (PHASE3)
- Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control (PHASE4)
- Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Other antidiabetic therapies CI brief — competitive landscape report
- Other antidiabetic therapies updates RSS · CI watch RSS
- AstraZeneca portfolio CI